Evidence map›Paper›PMID 39726772›Full record

ArticleJournal of pharmacology & clinical toxicology2024

A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule-1 Biomarker.

Lauren E Thompson, Avisek Ghimire, Xia Wen, Christine Kim, Juliana Choza, Cathleen L Doherty, Brian T Buckley, Daniel W Bowles, Cindy L O'Bryant, David G Pfister and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmacology & clinical toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lauren E ThompsonDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, USA.
Avisek GhimireDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, USA.
Xia WenEnvironmental and Occupational Health Sciences Institute, Rutgers University, USA.
Christine KimDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, USA.
Juliana ChozaDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, USA.
Cathleen L DohertyDepartment of Earth and Planetary Sciences, Rutgers University, USA.
Brian T BuckleyEnvironmental and Occupational Health Sciences Institute, Rutgers University, USA.
Daniel W BowlesCancer Center, University of Colorado Anschutz Medical Campus, USA.
Cindy L O'BryantCancer Center, University of Colorado Anschutz Medical Campus, USA.
David G PfisterHead and Neck Oncology Service, Memorial Sloan Kettering Cancer Center, USA.
Edgar A JaimesRenal Service, Memorial Sloan Kettering Cancer Center, USA.
Lauren M AleksunesEnvironmental and Occupational Health Sciences Institute, Rutgers University, USA.
Melanie S JoyDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI BRIAN T BUCKLEY · 1988 to 2026
$47.4M
Colorado Clinical and Translational Sciences Institute (CCTSI)UM1TR004399 · NCATS · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS, RONALD J. SOKOL · 2023 to 2026
$30.7M
New Jersey Alliance for Clinical Translational Science: NJ ACTSUL1TR003017 · NCATS · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI PANETTIERI, REYNOLD ALEXANDER · 2019 to 2023
$28.9M
TRAINING IN EVIRONMENTAL TOXICOLOGYT32ES007148 · NIEHS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI Lauren M Aleksunes · 1987 to 2026
$11.4M
NRSA Training CoreTL1TR002533 · NCATS · UNIVERSITY OF COLORADO DENVER · PI CICUTTO, LISA · 2018 to 2022
$3.0M
Drug Disposition and NephrotoxicityR01GM123330 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI ALEKSUNES, LAUREN M, JOY, MELANIE S · 2018 to 2021
$2.1M
Training in Molecular and Systems ToxicologyT32ES029074 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI Jared Michael Brown · 2019 to 2026
$1.1M
Pharmacokinetic and Pharmacogenomic Determinants of Cisplatin Kidney InjuryR21DK093903 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI ALEKSUNES, LAUREN M, JOY, MELANIE S · 2012 to 2013
$423k
NCATS NIH HHS TL1 TR002533NCATS NIH HHS UL1 TR003017NCATS NIH HHS UM1 TR004399NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA046934NCI NIH HHS P30 CA072720NIDDK NIH HHS R21 DK093903NIEHS NIH HHS P30 ES005022NIEHS NIH HHS T32 ES007148NIEHS NIH HHS T32 ES029074NIGMS NIH HHS R01 GM123330
6 · The paper itself

Abstract

Cisplatin is a platinum-based chemotherapeutic that causes acute kidney injury in over 30% of patients. The aim of this study was to develop a population pharmacokinetic/toxicodynamic (PKTD) model of cisplatin-induced kidney injury that incorporated plasma total platinum and urinary kidney injury molecule-1 (KIM-1) concentrations. Cancer patients receiving their first or second round of cisplatin-containing chemotherapy (n=39) were prospectively randomized to a 5-HT

Indexed as

5-HT3 AntagonistCisplatinKidney InjuryNephrotoxicityPharmacodynamicsPharmacokineticsToxicodynamics

Identifiers

PMID39726772
PMCPMC11671133

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.